Being the third most prevalent cardiovascular illness after myocardial infarction and stroke, Venous Thromboembolism (VTE), which includes pulmonary embolism (PE) and deep venous thrombosis (DVT), is a serious public health concern. According to reports, VTE is the second most common cardiovascular consequence, may have an impact on how long patients stay in the hospital for various medical and surgical conditions, and is the second most prevalent reason for an extended stay. The most significant clinical risk factors for VTE include major surgery and trauma, active malignancy, immobilisation, hospitalisation for acute medical disease, and pregnancy.
The signs and symptoms of both PE and DVT may be too general, hence proper clinical risk stratification techniques and diagnostic modalities must be used in order to provide a conclusive diagnosis. Anticoagulation is remains the cornerstone of the treatment, despite the introduction of numerous innovative therapeutics for varied Venous Thromboembolism (VTE) conditions. VTE is a disease that can be avoided, and using a prophylactic approach has shown to dramatically lessen the disease's impact.
